Characteristic | Training cohort | Validation cohort | ||||
---|---|---|---|---|---|---|
UnivariateP | Multivariate | UnivariateP | Multivariate | |||
HR (95% CI) | P | HR (95% CI) | P | |||
Cancer-specific survival | Â | Â | Â | Â | Â | Â |
Age (years) | 0.276 | Â | Â | 0.136 | Â | Â |
Gender (male vs female) | 0.929 | Â | Â | 0.138 | Â | Â |
Tumor size (cm) | <0.001 | 1.071(0.973-1.180) | 0.163 | 0.001 | 1.008(0.850-1.195) | 0.932 |
TNM stage (III + IV vs I + II) | <0.001 | 3.847(2.195-6.743) | <0.001 | <0.001 | 18.197(6.053-54.701) | <0.001 |
Fuhrman grade (3 + 4 vs 1 + 2) | 0.001 | 2.308(1.342-3.970) | 0.003 | <0.001 | 3.648(1.314-10.126) | 0.014 |
Necrosis (present vs absent) | 0.015 | 1.183(0.657-2.127) | 0.578 | 0.014 | 1.270(0.505-3.197) | 0.614 |
ECOG PS (≥1 vs 0) | <0.001 | 2.750(1.496-5.056) | 0.001 | <0.001 | 7.059(2.233-22.311) | 0.001 |
CSF-1 (high vs low) | 0.004 | 2.609(1.432-4.755) | 0.002 | 0.004 | 4.435(1.478-13.308) | 0.008 |
Recurrence-free survival | Â | Â | Â | Â | Â | Â |
Age (years) | 0.113 | Â | Â | 0.661 | Â | Â |
Gender (male vs female) | 0.972 | Â | Â | 0.726 | Â | Â |
Tumor size (cm) | 0.001 | 1.081(0.981-1.191) | 0.118 | 0.001 | 1.154(0.964-1.381) | 0.121 |
TNM stage (III + IV vs I + II) | <0.001 | 3.095(1.779-5.383) | <0.001 | <0.001 | 10.053(3.198-31.602) | <0.001 |
Fuhrman grade (3 + 4 vs 1 + 2) | 0.002 | 2.196(1.282-3.760) | 0.004 | <0.001 | 2.957(1.197-7.306) | 0.019 |
Necrosis (present vs absent) | 0.012 | 1.180(0.649-2.145) | 0.590 | 0.010 | 1.156(0.447-2.990) | 1.156 |
ECOG PS (≥1 vs 0) | 0.001 | 2.049(1.082-3.878) | 0.028 | 0.037 | 5.103(1.494-17.428) | 0.010 |
CSF-1 (high vs low) | 0.006 | 2.075(1.168-3.687) | 0.013 | 0.021 | 3.460(1.328-9.012) | 0.012 |